Several preclinical studies of HPV-associated tumors have shown that combining anti-PD-1 antibodies with therapeutic HPV16 E6/E7 vaccines significantly increases tumor clearance and more CD8+ T cells [40,41]. The gene discussed is PDCD1; the disease is neoplasm.